Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1959

Sort by

Sort Order Select

Journal Articles

Poor prognosis is ZAP70’ed into focus in CLL

Adam J. Linley, Joseph R. Slupsky

Blood (2021) 137 (26): 3586–3587.

https://doi.org/10.1182/blood.2021011270

Published: 2021

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska

Blood (2020) 135 (8): 584–588.

https://doi.org/10.1182/blood.2019002401

Published: 2020

Includes: Supplemental data

Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Blood (2019) 134 (Supplement_1): 3805.

https://doi.org/10.1182/blood-2019-129262

Published: 2019

Journal Articles

Syk Plays an Essential Role in Phagosome-Lysosome Fusion By Facilitating Actin-Remodeling in Complement-Mediated Phagocytosis

Yumi Tohyama, PhD, Hiroyuki Tabata, PhD, Kaoru Tohyama, MD PhD

Blood (2019) 134 (Supplement_1): 2315.

https://doi.org/10.1182/blood-2019-125061

Published: 2019

Journal Articles

Endothelial JAK3 Expression Enhances Pro-Hematopoietic Angiocrine Function of Sinusoidal Endothelial Cells

José Gabriel Barcia Durán, BS

Blood (2019) 134 (Supplement_1): 2488.

https://doi.org/10.1182/blood-2019-122449

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Nicholas D'Cunha, MD, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Upama Sharma, Nimesh Adhikari, MD, Ye Aung, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5479.

https://doi.org/10.1182/blood-2019-123172

Published: 2019

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5309.

https://doi.org/10.1182/blood-2019-126913

Published: 2019

Journal Articles

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

Blood (2019) 134 (Supplement_1): 5694.

https://doi.org/10.1182/blood-2019-128031

Published: 2019

Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD

Blood (2019) 134 (Supplement_1): 4200.

https://doi.org/10.1182/blood-2019-132038

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD

Blood (2019) 134 (Supplement_1): 2526.

https://doi.org/10.1182/blood-2019-128574

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Poor prognosis is ZAP70’ed into focus in CLL

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Syk Plays an Essential Role in Phagosome-Lysosome Fusion By Facilitating Actin-Remodeling in Complement-Mediated Phagocytosis

Endothelial JAK3 Expression Enhances Pro-Hematopoietic Angiocrine Function of Sinusoidal Endothelial Cells

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only